Filter
Exclude
Time range
-
Near
$AEYE $BHF $CGEM $DRGN Guys, Don't miss the next move in a few hours:- futuretrading.net

42
✅ 𝐂𝐆𝐄𝐌 : 𝟐𝟏 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐢𝐬𝐞𝐬 𝐫𝐞́𝐜𝐨𝐦𝐩𝐞𝐧𝐬𝐞́𝐞𝐬 𝐩𝐨𝐮𝐫 𝐥𝐞𝐬 𝟐𝟎 𝐚𝐧𝐬 𝐝𝐞 𝐥𝐚 𝐂𝐡𝐚𝐫𝐭𝐞 𝐑𝐒𝐄, 𝐮𝐧 𝐥𝐚𝐛𝐞𝐥 𝐪𝐮𝐢 𝐜𝐨𝐦𝐩𝐭𝐞 𝐝𝐞́𝐬𝐨𝐫𝐦𝐚𝐢𝐬 𝟏𝟓𝟐 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐢𝐬𝐞𝐬 𝐞𝐧𝐠𝐚𝐠𝐞́𝐞𝐬 📑 Actualité RH Maroc Vingt ans après le lancement de sa Charte de Responsabilité Sociétale des Entreprises (RSE), la Confédération Générale des Entreprises du Maroc (CGEM) confirme l’ancrage progressif de la responsabilité sociétale dans le paysage économique national. À l’occasion d’une cérémonie organisée à Casablanca, 21 entreprises ont obtenu ou renouvelé le Label RSE de la Confédération. Une distinction qui concerne désormais 152 entreprises et qui s’impose progressivement comme une référence en matière de gouvernance durable, d’impact social et de performance responsable. 👉 drh.ma/cgem-21-entreprises-r… #DRH #Maroc #RH
9
🚨 $CUE Strengthening Leadership for the Next Phase Cue Biopharma is entering a new phase of growth after announcing a major board transition and the addition of two experienced biotech leaders to its Board of Directors. ✅ Daniel Camardo has helped lead multiple commercial launches and blockbuster therapies throughout his biotech career ✅ Viola Meehan brings more than 30 years of financial leadership experience across biotechnology companies ✅ The board refresh follows several leadership changes made throughout 2026 as CUE positions for future growth ✅ The new directors add valuable commercial, financial, and operational expertise as the company advances its pipeline Beyond the leadership changes, Cue remains focused on advancing CUE-401 and expanding its autoimmune disease strategy while pursuing additional partnership and licensing opportunities. A stronger leadership team, a growing pipeline, and programs targeting multi billion dollar autoimmune and inflammatory disease markets could keep CUE firmly on investors' watchlists throughout 2026. Communicated Disclaimer: stockresearchtoday.com/cue/ Sector Peers: $IMNN $IOVA $ADAP $HOOK $ACHV $ANIX $TCRT $NKTX $AUTL $CGEM $VYGR $CRBU
4
11
3,993
Quelque 21 nouvelles entreprises ont décroché la label RSE décerné par la Confédération Générale des Entreprises du Maroc (CGEM) lors d’une cérémonie présidée, lundi, par le président du patronat, Mehdi Tazi. ow.ly/mktr50ZcfwF
128
$CGEM June 10 Immunology Day: positive CLN-978/velinotamig data, price target raised to $46. Stock -9% on the day. The market doesn’t reward early data. It uses it as an exit. Sell the news is not an anomaly. It’s the playbook.
46
Replying to @sinbadnetwork
I hope one can use wallet address generated from the contract address share on SINBAD NETWORK telegram channel, that of SNBD & CGEM ?
1
2
632
La CGEM célèbre les 20 ans de sa Charte RSE ⏩⏩leseco.ma/?p=307546
54
M. Mehdi Tazi a présidé hier la cérémonie de remise des trophées 🏆 du Label RSE 2026, organisée à l’occasion du 20ᵉ anniversaire de la Charte #RSE de la CGEM, sur le thème : « 20 ans de la Charte RSE : de l’engagement à l’impact ».
136
Le Label RSE de la CGEM a été attribué pour la première fois à AXA Services, BOTTU, CGI (Compagnie Générale Immobilière), Crédit Agricole du Maroc, Frigo Process, Pharma 5, Rabat Région Mobilité, Red Med Private Equity, S2M et Wafa IMA Assistance. ⬆️ lavieeco.com/affaires/la-cge…
83
$AEYE $BHF $CGEM $DRGN Guys, Don't miss the next move in a few hours:- futuretrading.net

117
If you’re glued to the market all day but still can’t lock down solid trading opportunities, consider following 👉@thomasHa80. He’s dropped some really sharp market takes lately, including: ✅ $LMRI$SSP$CGEM. His content’s definitely worth adding to your follow list.
273
Je reprends ma casquette de consultant sur la zlecaf pour rappeler que c'est un projet continental, véritable rampe de lancement de l'économie Africaine,mérite une communication adéquate et de proximité notamment avec les associations professionnelles ( amith, cgem,asmex,imme...)
24
Cullinan Therapeutics $CGEM is a clinical-stage biopharmaceutical innovator developing highly differentiated targeted therapies for complex oncology and autoimmune diseases. Armed with a formidable cash reserve of over $393 million that extends its operational runway into 2029, the company is well-equipped to fund its ambitious pipeline without immediate shareholder dilution. The current market assigns a conservative valuation to these assets, creating a highly asymmetric risk-reward profile as its lead oncology drug zipalertinib approaches a critical FDA approval date in early 2027. Furthermore, promising early clinical data for its off-the-shelf immunology candidate CLN-978 demonstrates profound disease-modifying potential that could soon disrupt the traditional CAR-T therapy landscape. Will these upcoming regulatory milestones and pivotal clinical readouts successfully transform this pre-commercial biotech into a highly profitable market leader?
1
311